UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053079
Receipt number R000060524
Scientific Title Epidemiological study of intestinal permeability in patients with neurological diseases
Date of disclosure of the study information 2023/12/18
Last modified on 2023/12/12 20:26:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Epidemiological study of intestinal permeability in patients with neurological diseases

Acronym

Epidemiological study of intestinal permeability in patients with neurological diseases

Scientific Title

Epidemiological study of intestinal permeability in patients with neurological diseases

Scientific Title:Acronym

Epidemiological study of intestinal permeability in patients with neurological diseases

Region

Japan


Condition

Condition

neurological diseases

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To identify intestinal permeability in each of neurological disease

Basic objectives2

Others

Basic objectives -Others

Identification of the frequency and severity of intestinal permeability in each of neurological diseases

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To evaluate the frequency of intestinal permeability and its association with severity and prognosis in each of neurological disease

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

After fasting for at least 12 hours, drink 10 g of lactulose and 2 g of mannitol dissolved in 250 mL of water, and collect a portion of the urine after storing it for 6 hours.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. patients with neurological disorders who are 20 years of age or older at the time consent is obtained
2. patients who have given written consent to participate in this study

Key exclusion criteria

1. patients with galactosemia
2. patients with severe intolerance to sugar alcohols or allergy to foods containing sugar alcohols
3. patients who are taking alpha-glucosidase
4. patients who are deemed unsuitable by the physician in charge
5. patients whose consent could not be obtained

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Syuuichirou
Middle name
Last name Suzuki

Organization

Sapporo Medical University

Division name

Division of Neurology

Zip code

0608543

Address

South-1, West-16, Chuo-ku, Sapporo

TEL

0116112111(38210)

Email

ssuzu@sapmed.ac.jp


Public contact

Name of contact person

1st name Syuuichirou
Middle name
Last name Suzuki

Organization

Division of Neurology

Division name

Division of Neurology

Zip code

0608543

Address

South-1, West-16, Chuo-ku, Sapporo

TEL

0116112111(38210)

Homepage URL


Email

ssuzu@sapmed.ac.jp


Sponsor or person

Institute

Department of Neurology, Sapporo Medical University

Institute

Department

Personal name

Syuuichirou Suzuki


Funding Source

Organization

Division of Neurology, Sapporo Medical University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

the Institutional Review Board of Sapporo Medical University Hospital

Address

South-1, West-17, Chuo-ku, Sapporo

Tel

0116112111

Email

ji-rskk@sapmed.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2023 Year 07 Month 10 Day

Date of IRB

2023 Year 07 Month 13 Day

Anticipated trial start date

2023 Year 12 Month 13 Day

Last follow-up date

2027 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 12 Month 12 Day

Last modified on

2023 Year 12 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060524


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name